Doxorubicin hydrochloride (adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography

Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity

“…Prolonged infusion of doxorubicin seems to reduce chronic cardiotoxicity (Speyer et al, 1985). This observation supports the hypothesis that cardiotoxicity is related to repeated high concentrations of the drug, which would induce an acute myocarditis-like effect (Shapira et al, 1990), rather than to the total cumulative dose (Alexander et al, 1979): the sum of repeated acute toxic effects would lead to the chronic damage (Piver et al, 1985). Our preliminary data suggest a relationship between intracellular Mg concentrations and anthracycline-induced acute toxic effects on the heart: might the monitoring of intracellular Mg levels have some value in predicting the development of the chronic damage?…”

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

“…ERNA reproducibly detects relatively small changes, and ERNA monitoring cost effectively permits doxorubicin administration with a low risk of clinical heart failure [24][25][26]28]. A comparison between radionucleotide and echocardiographic LVEF showed better intra-and inter-observer reproducibility with the radionucleotide LVEF [27].…”

Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies

“…Eight of 32 patients (25%) presented with a decrease > 10% in the ejection fraction. A similar incidence of decrease in ejection fraction after doxorubicin therapy has been noted before (Piver et al 1985). In patients with a low risk of heart failure, treatment with doxorubicin, at an empirical maximal dose of < 500 rag/ m z, has proven effective as a management guide (Schwartz et al 1987).…”

“…It has been shown that after reaching a cumulative dose of 500 mg/m 2, additional treatment produces an increasing incidence of clinically significant, and often fatal, cardiomyopathy (Piver et al 1985). Therefore, cancer patients under anthracycline therapy require cardiac monitoring to assess cardiotoxicity.…”